Clinical trialNCT02573896Active, not recruitingPhase 1Interventional

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

SponsorNew Approaches to Neuroblastoma Therapy ConsortiumEnrollment13Neuroblastoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of dinutuximab and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with dinutuximab, for treatment of children with refractory or recurrent neuroblastoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Araz Marachelian, MD, MS
Children's Hospital Los Angeles
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital Los Angeles
Los Angeles, California, United States
Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Aflac Cancer Center and Blood Disorders Service of Children'S Healthcare of Atlanta - Egleston Campus
Atlanta, Georgia, United States
University of Chicago Comer Children'S Hospital
Chicago, Illinois, United States
Childrens Hospital Boston, Dana-Farber Cancer Institute.
Boston, Massachusetts, United States
C.S Mott Children'S Hospital
Ann Arbor, Michigan, United States
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Nationwide Children'S Hospital
Columbus, Ohio, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Cook Children'S Healthcare System
Fort Worth, Texas, United States
Seattle Children'S Hospital
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DinutuximabLenalidomide →Natural Killer Cell

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Jan 2019
Primary completion: 31 Dec 2026
Completion: 31 Dec 2026
Last update posted: 23 Mar 2026
Registered enrollment: 13
Registry id: NCT02573896

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.